KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Research & Development: 2013-2025

Historic Research & Development for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to $77.1 million.

  • Xenon Pharmaceuticals' Research & Development rose 35.25% to $77.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.7 million, marking a year-over-year increase of 42.04%. This contributed to the annual value of $210.4 million for FY2024, which is 25.60% up from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Research & Development stood at $77.1 million, which was up 2.76% from $75.0 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Research & Development registered a high of $77.1 million during Q3 2025, and its lowest value of $16.3 million during Q1 2021.
  • For the 3-year period, Xenon Pharmaceuticals' Research & Development averaged around $53.7 million, with its median value being $49.7 million (2024).
  • Data for Xenon Pharmaceuticals' Research & Development shows a peak YoY soared of 104.11% (in 2023) over the last 5 years.
  • Xenon Pharmaceuticals' Research & Development (Quarterly) stood at $21.9 million in 2021, then soared by 59.14% to $34.8 million in 2022, then climbed by 17.93% to $41.1 million in 2023, then spiked by 44.79% to $59.5 million in 2024, then skyrocketed by 35.25% to $77.1 million in 2025.
  • Its last three reported values are $77.1 million in Q3 2025, $75.0 million for Q2 2025, and $61.2 million during Q1 2025.